They have an innovative drug, but some cash problems. If I read the sec filings correctly, the patents expire on their depression drug, so if they want the patents extended, they'll have to find some cash and do some quick clinical trials.
They recently settled w/ one of their creditors, but I'm not sure if there are more creditors remaining or not.
Visit my biotech investing board!: investorshub.advfn.com/boards/board.aspx?board_id=16653
GLTA.